Cisplatin [or cis-diamminedichloroplatinum, Pt(NH₃)₂Cl₂] is the first member of platinum-containing anti-cancer drugs.  It binds DNA and causes DNA crosslinking which ultimately triggers apoptosis (programmed cell death). The MicroMolar Cisplatin Assay Kit (Catalog number CPT200) is designed for throughput measurement of micromolar concentrations of Cisplatin.  The assay is based on the light absorbance at 535 nm.  The assay kit can be used for assays of cisplatin in drug discovery, drug development, pharmaceutical samples and biological samples.

The MicroMolar Cisplatin Assay Kit (Catalog number CPT200) includes 4 ml of Reagent A, 0.080 ml of 50 x Reagent B, and 2 ml of 10 x Reagent C.  It is for 200 assays using 96-well plates.  Cuvettes may also be used for measurements.

References:                                       

RYUMON S. et al, Ammonium tetrathiomolybdate enhances the antitumor effect of cisplatin via the suppression of ATPase copper transporting beta in head and neck squamous cell carcinoma. ONCOLOGY REPORTS, DOI:  10.3892/or.2019.7367 (2019).

Panneerselvam J. et al, DCLK1 regulates tumor stemness and cisplatin resistance in non-small cell lung cancer via ABCD-member-4. Molecular Therapy. May (2020).